Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Johnson and Johnson | 173 |
| 2 | Gilead Sciences Inc | 105 |
| 3 | Merck and Co Inc | 100 |
| 4 | Amgen Inc | 52 |
| 5 | Arcus Biosciences Inc | 47 |
| 6 | C4 Therapeutics Inc | 43 |
| 7 | Eli Lilly and Co | 43 |
| 8 | Jiangsu Hengrui Medicine Co Ltd | 35 |
| 9 | Bristol Myers Squibb Co | 30 |
| 10 | Chinese Academy of Sciences | 25 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 2,207 |
| 2 | C07D | Heterocyclic compounds | 2,036 |
| 3 | A61K | Medicinal preparations | 1,777 |
| 4 | C07C | Acyclic and carbocyclic compounds | 362 |
| 5 | C07K | Peptides | 282 |
| 6 | C07H | Sugars and derivatives | 199 |
| 7 | C07F | Organometallic compounds | 198 |
| 8 | C07B | General methods of organic chemistry | 163 |
| 9 | Y02P | Climate change mitigation: production | 145 |
| 10 | C12N | Microorganisms, enzymes | 137 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | 2007 | Ionis Pharmaceuticals Inc | 671 |
| AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | 2017 | C4 Therapeutics Inc | 254 |
| 5′-modified bicyclic nucleic acid analogs | 2009 | Ionis Pharmaceuticals Inc | 371 |
| 5′-modified bicyclic nucleic acid analogs | 2011 | Ionis Pharmaceuticals Inc | 267 |
| HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | 2017 | C4 Therapeutics Inc | 138 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 2 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Brian Schwartz | Arqule (United States) | 10 |
| 2 | Giovanni Abbadessa | Arqule (United States) | 6 |
| 3 | Ronald E. Savage | Arqule (United States) | 4 |
| 4 | Carlotta Ranieri | University of Bari Aldo Moro | 3 |
| 5 | Kimloan Nguyen | National Center for Advancing Translational Sciences | 3 |
| 6 | Sudharshan Eathiraj | Arqule (United States) | 3 |
| 7 | Yi Yu | Arqule (United States) | 3 |
| 8 | Kyeong Ri Yu | National Center for Advancing Translational Sciences | 3 |
| 9 | Xin Xu | National Center for Advancing Translational Sciences | 3 |
| 10 | Pranav Shah | National Center for Advancing Translational Sciences | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092 | 2015 | 122 | PI3K/AKT/mTOR signaling in cancer |
| Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome | 2019 | 94 | Platelet Disorders and Treatments |
| In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS) | 2018 | 83 | Vascular Malformations and Hemangiomas |
| Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome | 2021 | 74 | PI3K/AKT/mTOR signaling in cancer |
| Schizophrenic inability to disattend from strong aspects of meaning. | 1976 | 71 | Schizophrenia research and treatment |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of miransertib?
Which companies hold the most patents related to miransertib?
What was the trend in patent filings for miransertib between 2023 and 2024?
What clinical research has been published on miransertib's use in genetic disorders?
Which CPC subclasses dominate the patent landscape for miransertib?